UK-Born Healthtech Startup Bioniq To Be Acquired By US-Based Health And Wellness Company Herbalife In US$150 Million Deal

Bioniq, a UK-born personalized supplements company, has been acquired by Herbalife, a US-headquartered global nutrition and wellness company, in a deal valued at US$150 million. The transaction, which shall see a purchase price of $55 million paid over five years, also includes up to $95 million of contingent payments based on future performance.

Founded in 2019, Bioniq develops tailored supplement formulas using blood biomarker data, individual health profiles, and a proprietary personalization engine. The London-born healthtech went on to make inroads into the UAE in 2021, with it since expanding across the Gulf bolstered by partnerships with entities like the Department of Culture and Tourism in Abu Dhabi and Al Borg Diagnostics in Riyadh.

The acquisition is thus set to enable Bioniq’s science-driven, personalized supplementation platform to scale globally through Herbalife’s extensive infrastructure that spans 95 markets and boasts of over two million distributors as well as millions of customers around the world. Bioniq’s personalized nutritional supplements are expected to be offered later this year through Herbalife independent distributors for customers in select countries in Europe and the US, with additional markets to follow. 

Speaking to Inc. Arabia, Bioniq co-founder and President Vadim Fedotov, who will join Herbalife’s leadership team after the transaction, said, “From day one, our mission at Bioniq has been to make health accessible, measurable, and truly personalized. As we scaled, it became clear that achieving this vision globally requires not only cutting-edge science and technology, but also the infrastructure to reach millions of people in a meaningful way. Herbalife brings an unparalleled global platform, deep expertise in nutrition, and a powerful community-driven distribution model. By joining forces, we can accelerate our impact—taking our data-driven, individualized approach to health to a truly global standard.”

Bioniq has been expanding across the Gulf since entering the UAE market in 2021. 

Herbalife, which was established in 1980, describes itself as “the number one active and lifestyle nutrition brand in the world.” In February this year, soccer superstar Cristiano Ronaldo, an investor in Bioniq, had acquired a 10 percent equity interest in HBL Pro2col Software, LLC, an indirect wholly-owned subsidiary of Herbalife that holds the Pro2col technology. Pro2col is Herbalife's next-generation, digital, personalized health and wellness operating system designed to drive daily engagement, sustainable behavior change, and measurable outcomes through a structured, data-driven approach to wellness.

In a statement, Stephan Gratziani, CEO of Herbalife, said, “The future of health and wellness is increasingly personalized and data-driven. By combining Bioniq’s technology with our global infrastructure and Pro2col platform, we are uniquely positioned to deliver personalized nutrition to millions of consumers worldwide.”

Ronaldo added, “Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level. As a longtime Herbalife and Bioniq user, I’ve experienced firsthand how a tailored approach to nutrition can help optimize performance. I’m delighted to see Bioniq’s personalized supplements become part of Herbalife’s expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness and performance."

The transaction, which is expected to close in the second quarter of 2026, will also see Herbalife obtain a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides. The call option provides Herbalife with strategic flexibility to evaluate potential longer-term opportunities in this area in a disciplined and capital-efficient manner. 

Pictured in the lead image is Herbalife CEO Stephan Gratziani with Bioniq co-founder and President Vadim Fedotov. All images courtesy Bioniq.